Biogen Inc

Research Biogen Inc (BIIB) on Bullrun: valuation model: 22.4% overvalued, market cap USD 33.34B, P/E 40.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

Bullrun's latest valuation model marks Biogen Inc as 22.4% overvalued; latest market cap is USD 33.34B; P/E is 40.0.

Peer valuation comparison

Latest P/E is 39.97x versus a Healthcare sector median of 24.61x (62.4% above).

Latest P/E is 39.97x versus a United States median of 23.85x (67.6% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 9.89BUSD 1.29BUSD 2.05B75.7%8.79USD 3.01BUSD 6.29BUSD 18.26B
FY2024USD 9.68BUSD 1.63BUSD 2.72B76.1%11.18USD 2.38BUSD 6.30BUSD 16.72B
FY2023USD 9.84BUSD 1.16BUSD 1.27B74.2%7.97USD 1.05BUSD 6.94BUSD 14.80B
FY2022USD 10.17BUSD 3.05BUSD 1.14B77.6%20.87USD 3.42BUSD 6.28BUSD 13.40B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-09USD 33.34B40.0n/an/a
20252025-12-31USD 25.84B20.0n/an/a
20242024-12-31USD 22.28B13.7n/an/a
20232023-12-29USD 37.50B25.7n/an/a
20222022-12-30USD 39.88B14.1n/an/a
20212021-12-31USD 35.27B23.1n/an/a

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA;

ETFs that hold Biogen Inc

Biogen Inc is one of the ten largest holdings of 14 ETFs that investors in Europe can buy. The 8 most traded of them:

ETFWeightTER
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)2.23%0.35%
iShares Healthcare Innovation UCITS ETF USD (Acc)1.47%0.40%
Invesco NASDAQ Next Generation 100 UCITS ETF Acc1.68%0.25%
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)2.18%0.35%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation3.45%0.60%
Amundi Global Gender Equality ETF Accumulation0.92%0.20%
UBS Global Gender Equality UCITS ETF USD acc1.37%0.20%
UBS Global Gender Equality UCITS ETF hCHF acc1.37%0.23%

Related stock research

United States stocks United States Healthcare stocks A-Z stock index

Other Healthcare stocks

Abbvie Inc (ABBV) AMGEN Inc (AMGN) Bristol-Myers Squibb Company (BMY) Gilead Sciences Inc (GILD) Johnson & Johnson (JNJ) Lilly(Eli) & Company (LLY) Mira Pharmaceuticals Inc (MIRA) Merck & Co Inc (MRK) Organon & Company (OGN) Pfizer Inc (PFE) Scilex Holding Company (SCLX) Agilent Technologies Inc (A)

Frequently asked questions

Is Biogen Inc overvalued or undervalued?

Bullrun's valuation model currently marks Biogen Inc as 22.4% overvalued.

What is Biogen Inc's market cap?

Biogen Inc's market capitalization is USD 33.34B.

What is Biogen Inc's P/E ratio?

Biogen Inc's price-to-earnings (P/E) ratio is 40.0.

What does Biogen Inc do?

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.